Discovery Park seeks new tenant for key facility
Discovery Park is seeking an anchor tenant for its 24,000 square-foot pilot scale manufacturing facility.
Building 518 in the Kent-based science park is suitable for pilot scale small molecule drug development and can be modified for biological manufacture.
Mayer Schreiber, CEO of Discovery Park, said: “2018 was an important year for Discovery Park, with appointment of Martino Picardo as chairman and further development of out strategy. In starting 2019 with a focus on an anchor tenant for the Building 518 manufacturing facility, a swell as further occupiers for Building 500, the evolution of the park continues.”
Discovery Park is seeking a single occupier for Building 518, which was formerly occupied by a repository drugs manufacturer.
It is also offering laboratory and office space in Building 500, the former home of Pfizer R&D and manufacturing, for other companies looking to expand.
Discovery Park spans 220 acres and has tenants including Agalimmune, Algaecytes, Centauri Therapeutics, Genea Biomedx, Salvensis, and Venomtech.
